TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

TG Therapeutics Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TG Therapeutics (TGTX), Insmed (INSM) and Solventu...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TGTX	$34.27	+2.64%	1.06M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TGTX	$34.27	+2.6%	1.06M
3
4
5
6

TGTX

TGTX

Get TG Therapeutics Inc. Data in Excel

Get TG Therapeutics Inc. Data in Excel